BSI-510
/ Biosion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 27, 2023
BSI-510, a novel bispecific molecule combining an anti-Siglec-15 antibody with cytokine GM-CSF for enhanced antitumor efficacy
(SITC 2023)
- "Conclusions BSI-510 is a first-in-class anti-Siglec-15×GM-CSF bispecific fusion molecule combining simultaneous reversal of T cell inhibition and M2/M1 macrophage repolarization. BSI-510 demonstrates favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies."
Clinical • Oncology • Solid Tumor • CSF2 • SIGLEC15
1 to 1
Of
1
Go to page
1